ES2351569B8 - Ligandos peptídicos de receptores de somatostatina. - Google Patents

Ligandos peptídicos de receptores de somatostatina. Download PDF

Info

Publication number
ES2351569B8
ES2351569B8 ES200901168A ES200901168A ES2351569B8 ES 2351569 B8 ES2351569 B8 ES 2351569B8 ES 200901168 A ES200901168 A ES 200901168A ES 200901168 A ES200901168 A ES 200901168A ES 2351569 B8 ES2351569 B8 ES 2351569B8
Authority
ES
Spain
Prior art keywords
somatostatine
receptors
peptide ligands
sstr4
sstr5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES200901168A
Other languages
English (en)
Other versions
ES2351569B1 (es
ES2351569A1 (es
Inventor
Antonio Parente Dueña
Berta Ponsati Obiols
Jimena Fernandez Carneado
Marc Gomez Caminals
Ribera Jordana I Lluch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BCN Peptides SA
Original Assignee
BCN Peptides SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200901168A priority Critical patent/ES2351569B8/es
Application filed by BCN Peptides SA filed Critical BCN Peptides SA
Priority to JP2012509037A priority patent/JP6162952B2/ja
Priority to BRPI1007654-9A priority patent/BRPI1007654B1/pt
Priority to CN201080019851.0A priority patent/CN102428371B/zh
Priority to PL10718582T priority patent/PL2427775T3/pl
Priority to CA2760977A priority patent/CA2760977C/en
Priority to EP10718582.9A priority patent/EP2427775B1/en
Priority to KR1020117029096A priority patent/KR101592064B1/ko
Priority to RU2011146931/04A priority patent/RU2525468C2/ru
Priority to ES10718582T priority patent/ES2897566T3/es
Priority to PT107185829T priority patent/PT2427775T/pt
Priority to MX2011011723A priority patent/MX2011011723A/es
Priority to HUE10718582A priority patent/HUE056400T2/hu
Priority to PCT/EP2010/056152 priority patent/WO2010128098A1/en
Priority to DK10718582.9T priority patent/DK2427775T3/da
Priority to AU2010244439A priority patent/AU2010244439B2/en
Priority to US13/319,285 priority patent/US8946154B2/en
Publication of ES2351569A1 publication Critical patent/ES2351569A1/es
Priority to IL216086A priority patent/IL216086A/en
Publication of ES2351569B1 publication Critical patent/ES2351569B1/es
Application granted granted Critical
Priority to ZA2011/08967A priority patent/ZA201108967B/en
Publication of ES2351569B8 publication Critical patent/ES2351569B8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/655—Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)

Abstract

Derivados peptídicos de fórmula general (I)#**FIGURA**#sus estereoisómeros, mezclas de los mismos y/o sus sales farmacéuticamente aceptables, un método de obtención, composiciones farmacéuticas que los contienen y su uso para el tratamiento, prevención y/o diagnóstico de aquellas condiciones, desórdenes y/o patologías donde los receptores de somatostatina sstr1, sstr2, sstr3, sstr4 y/o sstr5 se encuentran expresados.
ES200901168A 2009-05-07 2009-05-07 Ligandos peptídicos de receptores de somatostatina. Active ES2351569B8 (es)

Priority Applications (19)

Application Number Priority Date Filing Date Title
ES200901168A ES2351569B8 (es) 2009-05-07 2009-05-07 Ligandos peptídicos de receptores de somatostatina.
HUE10718582A HUE056400T2 (hu) 2009-05-07 2010-05-06 Szomatosztatinreceptorok peptidligandjai
CN201080019851.0A CN102428371B (zh) 2009-05-07 2010-05-06 生长抑素受体的肽配体
PL10718582T PL2427775T3 (pl) 2009-05-07 2010-05-06 Ligandy peptydowe receptorów somatostatyny
CA2760977A CA2760977C (en) 2009-05-07 2010-05-06 Peptide ligands of somatostatin receptors
EP10718582.9A EP2427775B1 (en) 2009-05-07 2010-05-06 Peptide ligands of somatostatin receptors
KR1020117029096A KR101592064B1 (ko) 2009-05-07 2010-05-06 소마토스타틴 수용체의 펩타이드 리간드
RU2011146931/04A RU2525468C2 (ru) 2009-05-07 2010-05-06 Пептидные лиганды соматостатиновых рецепторов
ES10718582T ES2897566T3 (es) 2009-05-07 2010-05-06 Ligandos peptídicos de receptores de somatostatina
PT107185829T PT2427775T (pt) 2009-05-07 2010-05-06 Ligandos peptídicos de recetores de somatostatina
JP2012509037A JP6162952B2 (ja) 2009-05-07 2010-05-06 ソマトスタチン受容体のペプチドリガンド
MX2011011723A MX2011011723A (es) 2009-05-07 2010-05-06 Ligandos peptidicos de receptores de somatostatina.
AU2010244439A AU2010244439B2 (en) 2009-05-07 2010-05-06 Peptide ligands of somatostatin receptors
DK10718582.9T DK2427775T3 (da) 2009-05-07 2010-05-06 Peptidligander af somatostatinreceptorer
PCT/EP2010/056152 WO2010128098A1 (en) 2009-05-07 2010-05-06 Peptide ligands of somatostatin receptors
US13/319,285 US8946154B2 (en) 2009-05-07 2010-05-06 Peptide ligands of somatostatin receptors
BRPI1007654-9A BRPI1007654B1 (pt) 2009-05-07 2010-05-06 Composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica
IL216086A IL216086A (en) 2009-05-07 2011-11-01 Peptides that are ligands of somatostatin receptors
ZA2011/08967A ZA201108967B (en) 2009-05-07 2011-12-06 Peptide ligands of somatostatin receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200901168A ES2351569B8 (es) 2009-05-07 2009-05-07 Ligandos peptídicos de receptores de somatostatina.

Publications (3)

Publication Number Publication Date
ES2351569A1 ES2351569A1 (es) 2011-02-08
ES2351569B1 ES2351569B1 (es) 2011-12-05
ES2351569B8 true ES2351569B8 (es) 2012-06-20

Family

ID=42357876

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200901168A Active ES2351569B8 (es) 2009-05-07 2009-05-07 Ligandos peptídicos de receptores de somatostatina.
ES10718582T Active ES2897566T3 (es) 2009-05-07 2010-05-06 Ligandos peptídicos de receptores de somatostatina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10718582T Active ES2897566T3 (es) 2009-05-07 2010-05-06 Ligandos peptídicos de receptores de somatostatina

Country Status (18)

Country Link
US (1) US8946154B2 (es)
EP (1) EP2427775B1 (es)
JP (1) JP6162952B2 (es)
KR (1) KR101592064B1 (es)
CN (1) CN102428371B (es)
AU (1) AU2010244439B2 (es)
BR (1) BRPI1007654B1 (es)
CA (1) CA2760977C (es)
DK (1) DK2427775T3 (es)
ES (2) ES2351569B8 (es)
HU (1) HUE056400T2 (es)
IL (1) IL216086A (es)
MX (1) MX2011011723A (es)
PL (1) PL2427775T3 (es)
PT (1) PT2427775T (es)
RU (1) RU2525468C2 (es)
WO (1) WO2010128098A1 (es)
ZA (1) ZA201108967B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777039B2 (en) * 2012-11-01 2017-10-03 Ipsen Pharma S.A.S. Somatostatin analogs and dimers thereof
AU2014323131B2 (en) * 2013-09-18 2018-08-09 Bcn Peptides S.A. Cortistatin analogues for the treatment of inflammatory and/or immune diseases
CN104086630B (zh) * 2014-06-25 2016-06-29 天津欧德莱生物医药科技有限公司 一种生长抑素受体激动剂多肽及其应用
CN104045690B (zh) * 2014-06-25 2016-06-08 舟山医院 生长抑素受体激动剂多肽及其应用
CN104045689B (zh) * 2014-06-25 2016-08-24 新乡医学院 一种关于生长抑素受体激动剂多肽及其应用
EP3265127B1 (en) 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
US11045482B2 (en) 2017-03-09 2021-06-29 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
US11261215B2 (en) 2017-09-19 2022-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Somatostatin prodrugs
ES2780274A1 (es) 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904594A (en) * 1973-07-02 1975-09-09 Salk Inst For Biological Studi Somatostatin and acylated des-(ala' 1', gly' 2') derivatives thereof
SU586837A3 (ru) * 1973-12-10 1977-12-30 Ауэрст, Маккенна Энд Харрисон Лимитед (Фирма) Способ получени производных соматостатина
US4133782A (en) 1976-06-07 1979-01-09 The Salk Institute For Biological Studies Somatostatin analogs with dissociated biological activities
US4211693A (en) * 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
US5364851A (en) * 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
IT1283134B1 (it) * 1996-07-08 1998-04-07 Dox Al Italia Spa Derivati sintetici e semisintetici di somatostatine utili nella stimolazione della crescita corporea, in particolare in
ES2264174T3 (es) * 1996-12-04 2006-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques (Scras) S.A.S Antagonistas de somatostatina.
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
FR2819508B1 (fr) * 2001-01-12 2005-01-21 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydorthiazoles, leurs procedes de preparation et leur utilisation therapeutiques
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
EP1283216A1 (en) * 2001-08-10 2003-02-12 Mallinckrodt Inc. Somatostatin analogues binding to all somatostatin receptor subtypes and their use
CN101336915B (zh) * 2008-08-12 2010-12-22 沈阳斯佳科技发展有限公司 一种具有抗肿瘤活性的药物组合物

Also Published As

Publication number Publication date
PL2427775T3 (pl) 2022-01-17
CA2760977C (en) 2016-04-26
US8946154B2 (en) 2015-02-03
AU2010244439B2 (en) 2013-10-03
CN102428371B (zh) 2015-08-12
BRPI1007654A2 (pt) 2016-02-23
CA2760977A1 (en) 2010-11-11
ES2351569B1 (es) 2011-12-05
IL216086A0 (en) 2012-01-31
CN102428371A (zh) 2012-04-25
DK2427775T3 (da) 2021-11-08
AU2010244439A1 (en) 2011-11-10
KR101592064B1 (ko) 2016-02-18
KR20120027302A (ko) 2012-03-21
ES2897566T3 (es) 2022-03-01
RU2525468C2 (ru) 2014-08-20
BRPI1007654B1 (pt) 2022-05-03
ZA201108967B (en) 2012-08-29
MX2011011723A (es) 2012-02-28
EP2427775A1 (en) 2012-03-14
JP2012526081A (ja) 2012-10-25
IL216086A (en) 2017-11-30
ES2351569A1 (es) 2011-02-08
EP2427775B1 (en) 2021-08-11
HUE056400T2 (hu) 2022-02-28
WO2010128098A1 (en) 2010-11-11
PT2427775T (pt) 2021-11-12
US20120122781A1 (en) 2012-05-17
JP6162952B2 (ja) 2017-07-12

Similar Documents

Publication Publication Date Title
ES2351569B8 (es) Ligandos peptídicos de receptores de somatostatina.
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
EA201170303A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида
CL2007003826A1 (es) Compuestos derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, antagonistas de receptores tipo trpv1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como trastornos gastrointestinales, trastornos respiratorios, psoriasis y depresion.
Martin et al. Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach
IL240749B (en) Polycyclic lysophosphatidic acid receptor antagonists, pharmaceutical compositions thereof, and uses thereof for the treatment or prevention of diseases or conditions
NI200900076A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso.
CO6300846A2 (es) Derivados heterociclicos que contienen azufre que tienen actividad inhibitoria de la beta secretasa
CL2008002863A1 (es) Compuestos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano sustituidos; el procedimiento de preparacion de los compuestos; su composicion farmaceutica; y uso en el tratamiento de la diabetes y enfermedades mediadas por glucocorticoides.
CR8838A (es) Uso medicinal de ligandos de receptor
MY154001A (en) Benzothiadiazepine compounds as modulators of ampa and nmda receptors
Contour-Galcéra et al. 3-Thio-1, 2, 4-triazoles, novel somatostatin sst2/sst5 agonists
ECSP089025A (es) Tratamiento de trastornos gastrointestinales con antagonistas de cgrp
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
EP2610429A3 (en) Downhole isolation methods and apparatus therefor
MX2013003662A (es) Metodos y composiciones para diagnostico y pronostico de lesion renal e insuficiencia renal.
JO3442B1 (ar) مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
IL311974A (en) Somatostatin receptor ligands such as octreotide for oral administration to treat the disease
RU2011146931A (ru) Пептидные лиганды соматостатиновых рецепторов
MX2011007600A (es) Derivados de oxadiazol beta carbonica como compuestos anti-diabeticos.
ECSP099029A (es) Nuevos análogos del péptido intestinal vasoactivo
GB2603387B (en) Monitoring of downhole components during deployment
FR2968477B1 (fr) Dispositif de decharge rapide d'un condensateur
Joshi et al. Synthesis and pharmacological study of some novel thiazolidinones
AR048059A1 (es) Formas cristalinas de benzoato de rizatriptano

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2351569

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20111205